HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease.

Abstract
AuthorsGiulio Cavalli, Alessandro Tomelleri, Giacomo De Luca, Corrado Campochiaro, Charles A Dinarello, Elena Baldissera, Lorenzo Dagna
JournalArthritis research & therapy (Arthritis Res Ther) Vol. 21 Issue 1 Pg. 54 (02 13 2019) ISSN: 1478-6362 [Electronic] England
PMID30760322 (Publication Type: Letter, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal, Humanized
  • Biomarkers
  • canakinumab
  • C-Reactive Protein
  • Ferritins
Topics
  • Adult
  • Antibodies, Monoclonal, Humanized (therapeutic use)
  • Biomarkers (blood)
  • Blood Sedimentation
  • C-Reactive Protein (analysis)
  • Exanthema (prevention & control)
  • Ferritins (blood)
  • Fever (prevention & control)
  • Humans
  • Remission Induction
  • Still's Disease, Adult-Onset (blood, drug therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: